<DOC>
	<DOCNO>NCT02601625</DOCNO>
	<brief_summary>This Phase I , Randomized , Placebo-Controlled , Double-Blind Study Assess Pharmacokinetics Safety anifrolumab follow Single-Dose administration healthy subject</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics Safety Single Doses Anifrolumab Healthy Subjects</brief_title>
	<detailed_description>This Phase I placebo-controlled study ass pharmacokinetics , safety tolerability 2 dos anifrolumab via subcutaneous ( SC ) route administration 1 dose anifrolumab via intravenous ( IV ) route healthy subject</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Provision sign date , write informed consent prior study specific procedure . 2 . Healthy male and/or female subject age 18 55 year . 3 . Females must negative pregnancy test screening . 4 . Females intact cervix must documentation Pap smear document malignancy . 5 . Have body mass index ( BMI ) 18 32 kg/m2 , inclusive , weigh least 50 kg . 6 . Must adequate abdominal adipose tissue SC injection . 7 . No history latent active TB prior screen . 8 . A chest radiograph evidence current active infection old active TB , malignancy , clinically significant abnormality within 6 month prior screen . 1 . History clinically significant disease disorder may put subject risk . 2 . History presence hepatic renal disease . 3 . Any clinically significant illness , medical/surgical procedure , trauma within 8 week participation . 4 . Any clinically significant chronic recent infection require hospitalization treatment antiinfectives . 5 . History cancer , apart squamous basal cell carcinoma skin . 6 . Any clinically significant lab , vital sign ECG abnormality judge investigator . 7 . Known history primary immunodeficiency , HIV splenectomy underlying condition . 8 . Any positive result screen hepatitis B , hepatitis C HIV antibody . 9 . History drug abuse within 1 year participation . 10 . Has receive another new chemical entity ( define compound approve marketing ) within 4 week 5 halflives prior participation . 11 . Previous receipt : Anifrolumab ; B celldepleting therapy ( include limit epratuzumab , ocrelizumab , rituximab ) â‰¤ 52 week prior screen . 12 . History allergy/hypersensitivity drug similar chemical structure class anifrolumab human gamma globulin therapy . 13 . Any live attenuate vaccine within 8 week prior participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Tolerability</keyword>
	<keyword>Anifrolumab</keyword>
	<keyword>Subcutaneous injection</keyword>
	<keyword>Intravenous infusion</keyword>
</DOC>